Agilon Health, INC Form 4 insider transactions

Agilon Health, Inc. Director Karen McLoughlin reported the acquisition of 78,724 restricted stock units, increasing her beneficial ownership to 151,890 shares.

Agilon Health, Inc. director Sharad Mansukani is set to acquire 78,724 restricted stock units (RSUs) on May 28, 2025, as part of a pre-arranged Rule 10b5-1 plan.

Agilon Health, Inc. Director Silvana Battaglia was granted 78,724 restricted stock units (RSUs) on May 28, 2025, aligning her interests with shareholders.

Timothy Gertsch, Chief Accounting Officer of agilon health, inc., reported the withholding of 193 shares of common stock valued at $2.22 per share to cover tax obligations related to restricted stock unit vesting.

Agilon Health's CEO, Steven Sell, reported disposing of shares to cover tax obligations related to restricted stock units and a transfer of shares into a trust.

Benjamin Shaker, Chief Markets Officer of Agilon Health, reported the disposal of common stock to cover income tax withholding obligations related to the settlement of restricted stock units.

Chief Accounting Officer Timothy Gertsch reports disposition of agilon health, inc. stock to cover tax obligations related to restricted stock units.

Denise Zamore, Chief Legal Officer of Agilon Health, reports the withholding of shares by the issuer to cover income tax obligations related to restricted stock units.

Girish Venkatachaliah, Chief Technology Officer of Agilon Health, reports disposals of common stock to cover income tax withholding obligations related to restricted stock units.

Jeffrey A. Schwaneke, CFO of Agilon Health, amends a previous filing to clarify details regarding stock purchases and holdings, including transactions made through a family trust and vesting schedules for restricted stock units and options.

Chief Legal Officer Denise Zamore reports acquisition of common stock and options in Agilon Health, Inc.

Girish Venkatachaliah, Chief Technology Officer of Agilon Health, reported the acquisition and disposal of common stock and the acquisition of options on April 1, 2025.

Benjamin Shaker, Chief Markets Officer of Agilon Health, reports acquisition and disposal of common stock and options in a recent SEC Form 4 filing.

Chief Accounting Officer Timothy Gertsch reports acquisition of restricted stock units and options in Agilon Health, along with holdings of common stock.

CEO Steven Sell reports acquisition and disposal of Agilon Health stock and options, including restricted stock units and options vesting over three years.

Agilon Health's CEO, Steven Sell, reports the vesting and settlement of performance-based restricted stock units (PSUs) and related tax withholding.

Benjamin Shaker, Chief Markets Officer of Agilon Health, reports the vesting and settlement of performance-based restricted stock units (PSUs) and shares withheld for tax obligations.

Girish Venkatachaliah, Chief Technology Officer of Agilon Health, reports the vesting and settlement of performance-based restricted stock units (PSUs) and shares withheld for tax obligations.

Agilon Health's Chief Accounting Officer, Timothy Gertsch, sold 187 shares of common stock to cover income tax obligations related to the vesting of restricted stock units.

Agilon Health director Karen McLoughlin purchased 25,000 shares of common stock at a weighted average price of $2.2034 per share on December 13, 2024.

Silvana Battaglia, a director at Agilon Health, purchased 25,062 shares of common stock at a weighted average price of $2.0058 per share.

Director Diana McKenzie has increased her holdings in Agilon Health through recent stock purchases.

An executive at Agilon Health, John William Wulf, purchased 45,000 shares of common stock in multiple transactions at a weighted average price of $2.181 per share.

Agilon Health's CEO, Steven Sell, recently purchased 20,000 shares of the company's common stock at an average price of $3.3594 per share.

Chief Accounting Officer Timothy Gertsch reports disposition of shares to cover tax obligations related to restricted stock units.

Chief Financial Officer of Agilon Health, Jeffrey A. Schwaneke, reports a series of transactions involving common stock and stock options, resulting in a net increase in his beneficial ownership.

Ronald A. Williams, a director of Agilon Health, Inc., reported the acquisition of 32,119 shares of common stock in the form of restricted stock units on May 29, 2024.

Director Diana McKenzie reported acquiring 32,119 shares of Agilon Health common stock on May 29, 2024, and now beneficially owns 38,819 shares.

Director Karen McLoughlin reports acquisition and disposal of Agilon Health (AGL) common stock and restricted stock units.

Director John William Wulf reports acquisition and disposal of Agilon Health (AGL) common stock and restricted stock units.